Navigation Links
Biostar Pharmaceuticals, Inc. Announces First Quarter 2010 Financial Results
Date:5/17/2010

tain our previous levels of profitability including on account of our ability to manage growth, intense competition, wage increases in China, our ability to attract and retain highly skilled professionals, time and cost overruns on fixed-price, fixed-time frame contracts, client concentration, our ability to successfully complete and integrate potential acquisitions, withdrawal of governmental fiscal incentives, political instability and regional conflicts and legal restrictions on raising capital or acquiring companies outside China. Additional risks that could affect our future operating results are more fully described in our United States Securities and Exchange Commission filings including our S-1 dated June 27, 2008, our Quarterly Report on Form 10-Q for the quarter ended September 30, 2009, our 10-K for the year ended December 31, 2008, and other recent filings. These filings are available at http://www.sec.gov . We may, from time to time, make additional written and oral forward-looking statements, including statements contained in our filings with the Securities and Exchange Commission and our reports to shareholders. We do not undertake to update any forward-looking statements that may be made from time to time by or on our behalf.

About Non-GAAP Financial Measures

To supplement the Company's consolidated financial statements, which statements are prepared and presented in accordance with GAAP, we use the following non-GAAP financial measures: non-GAAP adjusted net income, and non- GAAP adjusted EPS. The presentation of this financial information is not intended to be considered in isolati
'/>"/>

SOURCE Biostar Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. Biostar Pharmaceuticals, Inc. to Launch Xin Aoxing Oleanolic Acid Capsules in Beijing and Shanghai
2. Biostar Pharmaceuticals, Inc. Announces Second Quarter 2009 Financial Results
3. Biostar Pharmaceuticals, Inc. to Host Fiscal Year 2009 Second Quarter Earnings Conference Call on Friday, August 14, 2009 at 10:30 a.m. EDT
4. Biostar Pharmaceuticals, Inc. Retains HC International, Inc. to Implement Investor Relations Program
5. Biostar Pharmaceuticals, Inc. Reports Continued Revenues and Earnings Growth in First Quarter of 2009
6. Biostar Pharmaceuticals, Inc. Reports Record Revenues and Earnings for 2008
7. Inverness Medical Innovations to Close Cholestech, HemoSense and BioStar Facilities
8. Astellas Pharma Inc. to Acquire OSI Pharmaceuticals, Inc.
9. Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009
10. Poniard Pharmaceuticals, Inc. to Present Additional Cancer Treatment Data Found Significant by TapeBeat.Com Investors
11. Lotus Pharmaceuticals, Inc. Appoints OTC Division Head
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... , July 31, 2014 Rogne Bioscience, ... Francisco Bay Area , has acquired a licence ... Oxford,s commercialisation company. The potent anti-inflammatory activity of the ... at the University of Oxford,s Sir William Dunn ... which has raised over $1.5 million in seed financing, ...
(Date:7/31/2014)... ALBANY, New York , July 31, 2014 /PRNewswire/ ... published by Transparency Market Research "Electrodes for Medical Devices ... Fetal Scalp Electrodes, Therapeutic Electrodes - TENS, Pacemakers, Defibrillators, ... Share, Growth, Trends and Forecast, 2013 - 2019," the ... USD 633.6 million in 2012 and is estimated to ...
(Date:7/31/2014)... -- Senomyx , Inc. (NASDAQ: ... science technologies to discover, develop, and commercialize novel ... supply industries, today reported financial results for the ... quarter with $33.6 million in cash and highly ... quarter Senomyx achieved another important milestone with the ...
(Date:7/31/2014)... (PRWEB) July 31, 2014 Held at ... patients with an overview of the disease and its ... drug side effects, as well as updates on the ... to Dr. Sandy Srinivas for organizing this educational opportunity,” ... kidney cancer. “Sandy and her colleagues have put together ...
Breaking Biology Technology:Oxford licenses anti-inflammatory peptides to San Francisco Bay Area start-up 2Oxford licenses anti-inflammatory peptides to San Francisco Bay Area start-up 3Electrodes for Medical Devices Market Expected to Reach USD 1.45 Billion Globally in 2019: Transparency Market Research 2Electrodes for Medical Devices Market Expected to Reach USD 1.45 Billion Globally in 2019: Transparency Market Research 3Electrodes for Medical Devices Market Expected to Reach USD 1.45 Billion Globally in 2019: Transparency Market Research 4Electrodes for Medical Devices Market Expected to Reach USD 1.45 Billion Globally in 2019: Transparency Market Research 5Electrodes for Medical Devices Market Expected to Reach USD 1.45 Billion Globally in 2019: Transparency Market Research 6SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 2SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 3SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 4SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 5SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 6SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 7SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 8SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 9SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 10SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 11SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 12SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 13SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 14SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 15SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 16
... Calif., Oct. 15 ... INKN ), an innovative nanotechnology company developing ... industry, medical diagnostics and sensors and biotechnology research ... its first product offering – the StemDisc450™, a ...
... NORWALK, Conn., Oct. 15 UBM Medica today announces ... ) from MediSpecialty.com, Inc.   OBGYN.net is ... and patients.  The site provides article-based and multimedia content ... online forums – some of which have been running ...
... CoreLab Partners, Inc , the global entity resulting ... in February of this year, has launched a full ... as it relates to Dual Energy X-Ray Absorptiometry ( ... that we have formally launched state-of-the-art imaging solutions to ...
Cached Biology Technology:Shrink Nanotechnologies Unveils Product Image of Initial StemDisc450 Prototype 2Shrink Nanotechnologies Unveils Product Image of Initial StemDisc450 Prototype 3Shrink Nanotechnologies Unveils Product Image of Initial StemDisc450 Prototype 4UBM Medica Acquires Leading Online Community OBGYN.net 2UBM Medica Acquires Leading Online Community OBGYN.net 3CoreLab Partners Launches New DXA Imaging Service Offerings 2
(Date:8/1/2014)... Knowing what causes them at the molecular level is ... have created the most detailed map to date of ... blinding diseases, such as age-related macular degeneration. The high-resolution ... which supplies blood and oxygen to the outer retina, ... abundance of proteins in different areas of the choroid, ...
(Date:8/1/2014)... the conductive tissue through which plants transport carbohydrates and ... are capped at one end by a sieve plate ... turn form a network throughout a plant,s body. ... play an important role in carbon sequestration, yet so ... says Professor Yk Helariutta from the Institute of Biotechnology, ...
(Date:8/1/2014)... most diverse families in the ocean today -- marine ... more than 400 million years ago in the Silurian ... its modern members. This Geology study by ... on 25 July 2014, tracks the remarkable evolutionary expansion ... is origin, the Lucinidae family remained at very low ...
Breaking Biology News(10 mins):A map for eye disease 2Developmental regulation of important plant phloem components discovered 2Symbiotic survival 2Symbiotic survival 3Symbiotic survival 4Symbiotic survival 5Symbiotic survival 6Symbiotic survival 7Symbiotic survival 8Symbiotic survival 9Symbiotic survival 10Symbiotic survival 11Symbiotic survival 12Symbiotic survival 13Symbiotic survival 14
... Since its discovery in the 18th century, cocaine has ... reward centres in low doses, cocaine is extremely addictive ... potent compound did not evolve to ensnare humans in ... cocaine is a powerful insect neurotoxin, protecting coca bushes ...
... WA This Christmas season, think twice about spending ... tree. The good, old-fashioned methodkeeping your tree in a ... keep your tree green and healthy. Researchers have determined ... trees; in fact, in several cases the chemical retardants ...
... LANSING, Mich. Diversity is valuable socially, economically and ... has found that growing more corn to produce ethanol ... of beneficial insects to control pests, a loss valued ... states studied (Michigan, Iowa, Minnesota and Wisconsin). "Corn ...
Cached Biology News:Honeybees succumb to cocaine's allure 2Flame retardants prove ineffective on fresh-cut Christmas trees 2Diverse landscapes are better: Policymakers urged to think broadly about biofuel crops 2
...
... is collected off the clot from fasted Cynomolgus monkeys ... Available Anticoagulants: N-02: Citrate ... N-08: Potassium Oxalate N-10: EDTA (Na) ... N-07: CPD N-09: K3EDTA N-11: ...
3'-O-Methylguanosine 5'-Triphosphate, Sodium, 1 umol. Category: Nucleotides & Enzymes & Biochemicals, Nucleotides, Additional Nucleotide Products....
Recombinant Viral CCI/Fc Chimera, CF...
Biology Products: